Showing results (681-690 of 794) with videos related to

Sort By:
Pageof 80
Bioorganic & Medicinal Chemistry Letters|June 15, 2005
Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13Mark C Noe, Vijayalakshmi Natarajan, Sheri L Snow, et al.
The Prostate|May 10, 2022
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805Alicia K Morgans, Yu-Hui Chen, David F Jarrard, et al.
Clinical Genitourinary Cancer|May 28, 2014
Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancerBrandon A Mahal, Ayal A Aizer, David R Ziehr, et al.
Prostate Cancer and Prostatic Diseases|July 2, 2014
The association between insurance status and prostate cancer outcomes: implications for the Affordable Care ActB A Mahal, A A Aizer, D R Ziehr, et al.
European Journal of Cancer (Oxford, England : 1990)|August 12, 2017
Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysisLarysa H M Rydzewska, Sarah Burdett, Claire L Vale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2017
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate CancerWanling Xie, Meredith M Regan, Marc Buyse, et al.
The Prostate|March 3, 2015
The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancerRebecca E Graff, Andreas Pettersson, Rosina T Lis, et al.
Blood|September 7, 2007
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cellsMonica L Guzman, Randall M Rossi, Sundar Neelakantan, et al.
European Urology|May 22, 2024
Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized TrialsPraful Ravi, Wanling Xie, Marc Buyse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2025
A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate CancerSebastian Medina, Naoto Tokuyama, Kamal Hammouda, et al.
Pageof 80